Tryptase in drug-induced anaphylaxis: the need for acute and baseline values.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
aheadofprint
Résumé
The purpose of this narrative review was to summarize data and official recommendations purporting to paired tryptase determination in patients experiencing drug-induced anaphylaxis, published between January 1, 2023 and June 1, 2024. Three main lines of evidence obtained through paired acute and baseline tryptase determination were identified: diagnostic criterion for hypersensitivity reactions involving systemic mast cell activation; differential diagnostic criterion for hypersensitivity reactions involving other mechanisms of immediate reactions; and added value of acute and baseline tryptase levels for personalized management following drug-induced anaphylaxis: cause, risk of recurrence, underlying mast cell conditions including hereditary α-tryptasemia, familial clusters. The implementation of existing guidelines which consensually recommend paired tryptase measurement is a persistent unmet need hampering optimal diagnosis of drug-induced anaphylaxis and patient management. Another major unmet need is the lack of standardized recommendations for hereditary α-tryptasemia testing and counselling. Progress in this field is seen at a rapid pace, requiring significant efforts of continued medical education for practicing clinicians and laboratory specialists worldwide.
Identifiants
pubmed: 39079161
doi: 10.1097/ACI.0000000000001012
pii: 00130832-990000000-00142
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hofer V, Dolle-Bierke S, Francuzik W, et al. Fatal and near-fatal anaphylaxis: data from the European Anaphylaxis Registry and National Health Statistics. J Allergy Clin Immunol Pract 2024; 12:96–105. e108.
Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol 2024; 132:124–176.
Pouessel G, Tacquard C, Tanno LK, et al. Anaphylaxis mortality in the perioperative setting: epidemiology, elicitors, risk factors and knowledge gaps. Clin Exp Allergy 2024; 54:11–20.
Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy 2022; 77:357–377.
Alvarez-Arango S, Kumar M, Chow TG, Sabato V. Non-IgE-mediated immediate drug-induced hypersensitivity reactions. J Allergy Clin Immunol Pract 2024; 12:1109–1119.
Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832–836.
Jutel M, Agache I, Zemelka-Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy 2023; 78:2851–2874.
Yang BC, Castells MC. Utilizing biologics in drug desensitization. Curr Allergy Asthma Rep 2023; 23:1–11.
Klingebiel C, Belhocine W, Vitte J. Serum tryptase and drug hypersensitivity: why, how and what? A systematic review. Curr Opin Allergy Clin Immunol 2023; 23:294–299.
Valent P, Akin C, Arock M. Reversible elevation of tryptase over the individual's baseline: why is it the best biomarker for severe systemic mast cell activation and MCAS? Curr Allergy Asthma Rep 2024; 24:133–141.
Shin H, Lyons JJ. Alpha-tryptase as a risk-modifying factor for mast cell-mediated reactions. Curr Allergy Asthma Rep 2024; 24:199–209.
Michel M, Klingebiel C, Vitte J. Tryptase in type I hypersensitivity. Ann Allergy Asthma Immunol 2023; 130:169–177.
Le QT, Lyons JJ, Naranjo AN, et al. Impact of naturally forming human alpha/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia. J Exp Med 2019; 216:2348–2361.
Soto D, Malmsten C, Blount JL, et al. Genetic deficiency of human mast cell alpha-tryptase. Clin Exp Allergy 2002; 32:1000–1006.
Akin C, Siebenhaar F, Wechsler JB, et al. Detecting changes in mast cell numbers versus activation in human disease: a roadblock for current biomarkers? J Allergy Clin Immunol Pract 2024; 12:1727–1737.
Dudeck J, Kotrba J, Immler R, et al. Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation. Immunity 2021; 54:468–483. e465.
Bauer RN, Xie Y, Beaudin S, et al. Evaluation of the reproducibility of responses to nasal allergen challenge and effects of inhaled nasal corticosteroids. Clin Exp Allergy 2023; 53:1187–1197.
Vitte J, Sabato V, Tacquard C, et al. Use and interpretation of acute and baseline tryptase in perioperative hypersensitivity and anaphylaxis. J Allergy Clin Immunol Pract 2021; 9:2994–3005.
Madsen AT, Kristiansen HP, Winther-Larsen A. Short-term biological variation of serum tryptase. Clin Chem Lab Med 2024; 62:713–719.
Chovanec J, Tunc I, Hughes J, et al. Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv 2023; 7:1796–1810.
Mateja A, Wang Q, Chovanec J, et al. Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. J Allergy Clin Immunol 2022; 149:1010–1017. e1010.
Francois F, Mauff BL, Waeckel L, et al. Basal serum tryptase: a critical reconsideration of reference values. Allergy 2023; 78:3003–3006.
Valent P, Hoermann G, Bonadonna P, et al. The normal range of baseline tryptase should be 1 to 15 ng/mL and covers healthy individuals with HalphaT. J Allergy Clin Immunol Pract 2023; 11:3010–3020.
Vlaeminck N, Poorten MV, Nygaard Madsen C, et al. Paediatric perioperative hypersensitivity: the performance of the current consensus formula and the effect of uneventful anaesthesia on serum tryptase. BJA Open 2024; 9:100254.
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.
Liang L, Park KH, Lee JH, Park JW. Causes and diagnostic usefulness of tryptase measurements for anaphylaxis in a Korean Tertiary Care General Hospital. Yonsei Med J 2022; 63:1099–1105.
Srisuwatchari W, Tacquard CA, Borushko A, et al. Diagnostic performance of serial serum total tryptase measurement to differentiate positive from negative allergy testing among patients with suspected perioperative hypersensitivity. Clin Exp Allergy 2022; 52:334–344.
Haraguchi T, Horiuchi T, Takazawa T, et al. Comparison of the diagnostic performance of tryptase and histamine for perioperative anaphylaxis: a multicenter prospective study. Allergol Int 2024; S1323-8930(24)00049-2. doi: 10.1016/j.alit.2024.04.005. [Online ahead of print].
doi: 10.1016/j.alit.2024.04.005.
Takazawa T, Horiuchi T, Nagumo K, et al. The Japanese Epidemiologic Study for Perioperative Anaphylaxis, a prospective nationwide study: allergen exposure, epidemiology, and diagnosis of anaphylaxis during general anaesthesia. Br J Anaesth 2023; 131:159–169.
Escolano F, Yelamos J, Molto L, et al. Severe perioperative anaphylaxis: incidence in a tertiary hospital in Spain over a 20-year period. A historical cohort study. Rev Esp Anestesiol Reanim (Engl Ed) 2023; 70:17–25.
Gonzalez-Estrada A, Carrillo-Martin I, Morgenstern-Kaplan D, et al. A US-based multicenter retrospective report of perioperative anaphylaxis, 2010-2021. J Allergy Clin Immunol Pract 2024; 12:1594–1602.e9.
Au EYL, Mak HWF, Yeung MHY, et al. Ten-year outcomes of Perioperative Anaphylaxis Workup Study in Hong Kong (PAWS-HK): performance of diagnostic modalities. Ann Allergy Asthma Immunol 2023; 130:752–759. e751.
Pouessel G, Deschildre A, Dribin TE, et al. Refractory anaphylaxis: a new entity for severe anaphylaxis. J Allergy Clin Immunol Pract 2023; 11:2043–2048.
Carter MC, Park J, Vadas P, Worm M. Extrinsic and intrinsic modulators of anaphylaxis. J Allergy Clin Immunol Pract 2023; 11:1998–2006.
Beyens M, Toscano A, Ebo D, et al. Diagnostic significance of tryptase for suspected mast cell disorders. Diagnostics (Basel) 2023; 13:3662.
Ebo DG, De Puysseleyr LP, Van Gasse AL, et al. Mast cell activation during suspected perioperative hypersensitivity: a need for paired samples analysis. J Allergy Clin Immunol Pract 2021; 9:3051–3059. e3051.
Sverrild A, Carruthers J, Murthee KG, et al. Diagnostic value of a medical algorithm for investigation of perioperative hypersensitivity reactions. Allergy 2023; 78:225–232.
Foer D, Wien M, Karlson EW, et al. Patient characteristics associated with reactions to Mrgprx2-activating drugs in an Electronic Health Record-Linked Biobank. J Allergy Clin Immunol Pract 2023; 11:492–499. e492.
Sabato V, Ebo DG, Van Der Poorten MM, et al. Allergenic and Mas-related G protein-coupled receptor X2-activating properties of drugs: resolving the two. J Allergy Clin Immunol Pract 2023; 11:395–404.
Kunimura K, Akiyoshi S, Uruno T, et al. DOCK2 regulates MRGPRX2/B2-mediated mast cell degranulation and drug-induced anaphylaxis. J Allergy Clin Immunol 2023; 151:1585–1594. e1589.
Gonzalez de Olano D, Cain WV, Bernstein JA, Akin C. Disease spectrum of anaphylaxis disorders. J Allergy Clin Immunol Pract 2023; 11:1989–1996.
Elst J, van der Poorten MM, Van Gasse AL, et al. Tryptase release does not discriminate between IgE- and MRGPRX2-mediated activation in human mast cells. Clin Exp Allergy 2022; 52:797–800.
Pouessel G, Alonzo S, Divaret-Chauveau A, et al. Fatal and near-fatal anaphylaxis: the Allergy-Vigilance(R) Network data (2002-2020). Allergy 2023; 78:1628–1638.
Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016; 48:1564–1569.
Lyons JJ, Greiner G, Hoermann G, Metcalfe DD. Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions. J Allergy Clin Immunol Pract 2022; 10:1964–1973.
Chantran Y, Valent P, Arock M. KIT mutations and other genetic defects in mastocytosis: implications for disease pathology and targeted therapies. Immunol Allergy Clin North Am 2023; 43:651–664.
Kacar M, Rijavec M, Selb J, Korosec P. Clonal mast cell disorders and hereditary alpha-tryptasemia as risk factors for anaphylaxis. Clin Exp Allergy 2023; 53:392–404.
Beyens M, Sabato V, Ebo DG, et al. Drug-induced anaphylaxis uncommon in mastocytosis: findings from two large cohorts. J Allergy Clin Immunol Pract 2024; 12:1850–1862.e1.
Bonadonna P, Olivieri F, Jarkvist J, et al. Nonsteroidal anti-inflammatory drug-induced anaphylaxis infrequent in 388 patients with mastocytosis: a two-center retrospective cohort study. Front Allergy 2022; 3:1071807.
Niedoszytko M, Gorska A, Brockow K, et al. Prevalence of hypersensitivity reactions in various forms of mastocytosis: a pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry. Allergy 2024; doi: 10.1111/all.16132. [Online ahead of print].
doi: 10.1111/all.16132.
Jarkvist J, Gulen T. Diagnostic evaluation of hypersensitivity reactions to antibiotics in a large cohort of mastocytosis patients. Diagnostics (Basel) 2023; 13:2241.
Sordi B, Vanderwert F, Crupi F, et al. Disease correlates and clinical relevance of hereditary alpha-tryptasemia in patients with systemic mastocytosis. J Allergy Clin Immunol 2023; 151:485–493. e411.
Poto R, Marone G, Galli SJ, Varricchi G. Mast cells: a novel therapeutic avenue for cardiovascular diseases? Cardiovasc Res 2024; 120:681–698.
Elieh-Ali-Komi D, Bot I, Rodriguez-Gonzalez M, Maurer M. Cellular and molecular mechanisms of mast cells in atherosclerotic plaque progression and destabilization. Clin Rev Allergy Immunol 2024; 66:30–49.
Ebo DG, Lang DM, Ledford DK. Perioperative anaphylaxis: light at the end of the tunnel. J Allergy Clin Immunol Pract 2024; 12:1603–1604.
van der Poorten MM, Walschot M, Faber M, et al. Reliability of early and late testing for suspected perioperative hypersensitivity. J Allergy Clin Immunol Pract 2022; 10:1057–1062. e1052.